Literature DB >> 24698097

Bleomycin-induced fibrosis in MC1 signalling-deficient C57BL/6J-Mc1r(e/e) mice further supports a modulating role for melanocortins in collagen synthesis of the skin.

Markus Böhm1, Agatha Stegemann.   

Abstract

The melanocortin-1 receptor (MC1 ) binds α-melanocyte-stimulating hormone (α-MSH) with high affinity and has a physiological role in cutaneous melanin pigmentation. Previously, we reported that human dermal fibroblasts also express functional MC1 . α-MSH suppressed transforming growth factor-β1 - and bleomycin (BLM)-induced collagen synthesis in vitro and in vivo. Using MC1 signalling-deficient C57BL/6J-Mc1r(e/e) mice, we tested as to whether MC1 has a regulatory role on dermal collagen synthesis in the BLM model of scleroderma. Notably, mice with a C57BL/6J genetic background were previously shown to be BLM-non-susceptible. Interestingly, treatment of C57BL/6J-Mc1r(e/e) but not of C57BL/6J-wild-type mice with BLM increased cutaneous collagen type I content at RNA and protein level along with development of skin fibrosis. Cutaneous levels of connective tissue growth factor and monocyte chemotactic protein-1 were also increased in BLM-treated C57BL/6J-Mc1r(e/e) mice. Primary dermal fibroblasts from C57BL/6J-wt mice further expressed MC1 , suggesting that these cells are directly targeted by melanocortins to affect collagen production of the skin. Our findings support the concept that MC1 has an endogenous regulatory function in collagen synthesis and controls the extent of fibrotic stress responses of the skin.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  bleomycin; collagen; fibroblasts; fibrosis; neuropeptides

Mesh:

Substances:

Year:  2014        PMID: 24698097     DOI: 10.1111/exd.12409

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  7 in total

1.  LINC00937 suppresses keloid fibroblast proliferation and extracellular matrix deposition by targeting the miR-28-5p/MC1R axis.

Authors:  Jing Wan; Xiao-Lei He; Qi-Chao Jian; Zhi-Feng Fan; Ying Shi; Long-Fei Luo
Journal:  Histol Histopathol       Date:  2021-08-23       Impact factor: 2.303

2.  Melanogenic effect of dersimelagon (MT-7117), a novel oral melanocortin 1 receptor agonist.

Authors:  T Suzuki; Y Kawano; A Matsumoto; M Kondo; K Funayama; S Tanemura; M Miyashiro; A Nishi; K Yamada; M Tsuda; A Sato; K Morokuma; Y Yamamoto
Journal:  Skin Health Dis       Date:  2021-11-29

3.  Race and Melanocortin 1 Receptor Polymorphism R163Q Are Associated with Post-Burn Hypertrophic Scarring: A Prospective Cohort Study.

Authors:  Ravi F Sood; Anne M Hocking; Lara A Muffley; Maricar Ga; Shari Honari; Alexander P Reiner; Ali Rowhani-Rahbar; Nicole S Gibran
Journal:  J Invest Dermatol       Date:  2015-06-01       Impact factor: 8.551

4.  Multiplex serum protein analysis reveals potential mechanisms and markers of response to hyperimmune caprine serum in systemic sclerosis.

Authors:  Niamh Quillinan; Kristina E N Clark; Bryan Youl; Jeffrey Vernes; Deirdre McIntosh; Syed Haq; Christopher P Denton
Journal:  Arthritis Res Ther       Date:  2017-03-07       Impact factor: 5.156

5.  Widespread dynamic and pleiotropic expression of the melanocortin-1-receptor (MC1R) system is conserved across chick, mouse and human embryonic development.

Authors:  Anna C Thomas; Pauline Heux; Chloe Santos; Wisenave Arulvasan; Nita Solanky; Magalie E Carey; Dianne Gerrelli; Veronica A Kinsler; Heather C Etchevers
Journal:  Birth Defects Res       Date:  2018-01-08       Impact factor: 2.344

Review 6.  Antifibrotic and Anti-Inflammatory Actions of α-Melanocytic Hormone: New Roles for an Old Player.

Authors:  Roshan Dinparastisaleh; Mehdi Mirsaeidi
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-08

7.  Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis.

Authors:  Masahiro Kondo; Tsuyoshi Suzuki; Yuko Kawano; Shinji Kojima; Masahiko Miyashiro; Atsuhiro Matsumoto; Gabriela Kania; Przemysław Błyszczuk; Rebecca L Ross; Panji Mulipa; Francesco Del Galdo; Yun Zhang; Jörg H W Distler
Journal:  Arthritis Res Ther       Date:  2022-09-01       Impact factor: 5.606

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.